Effect of granulocytic chalone on acute myeloid leukaemia in man. A follow-up study.
Non-pyrogenic preparations of granulocytic chalone have been administered to patient with acute myeloid leukaemia (A.M.L.) who had relapsed after chalone-induced complete remission of the disease. Another regression of the leukaemia was obtained. Normal and leukaemic granulocytes were inhibited without effect on other cell types. Survival was prolonged in 4 other patients with A.M.L. Further investigations are needed to elucidate the therapeutic role of granulocytic chalone.
D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects; D001799:Blood Sedimentation; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006098:Granulocytes / Q000187:drug effects; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence; D012075:Remission, Spontaneous; D014527:Uric Acid / Q000097:blood
D006131:Growth Inhibitors; D006454:Hemoglobins; D014527:Uric Acid; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase